• Consensus Rating: Moderate Buy
  • Consensus Price Target: $296.95
  • Forecasted Upside: 13.02%
  • Number of Analysts: 19
  • Breakdown:
  • 0 Sell Ratings
  • 9 Hold Ratings
  • 10 Buy Ratings
  • 0 Strong Buy Ratings
$262.75
▼ -1.32 (-0.50%)

This chart shows the closing price for AMGN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Amgen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AMGN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AMGN

Analyst Price Target is $296.95
▲ +13.02% Upside Potential
This price target is based on 19 analysts offering 12 month price targets for Amgen in the last 3 months. The average price target is $296.95, with a high forecast of $360.00 and a low forecast of $200.00. The average price target represents a 13.02% upside from the last price of $262.75.

This chart shows the closing price for AMGN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 19 contributing investment analysts is to moderate buy stock in Amgen. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 10 buy ratings
  • 9 hold ratings
  • 0 sell ratings
10/26/2022
  • 0 strong buy ratings
  • 10 buy ratings
  • 9 hold ratings
  • 0 sell ratings
1/24/2023
  • 0 strong buy ratings
  • 10 buy ratings
  • 9 hold ratings
  • 0 sell ratings
4/24/2023
  • 0 strong buy ratings
  • 10 buy ratings
  • 9 hold ratings
  • 0 sell ratings
7/23/2023
  • 0 strong buy ratings
  • 10 buy ratings
  • 9 hold ratings
  • 0 sell ratings
10/21/2023
  • 0 strong buy ratings
  • 10 buy ratings
  • 9 hold ratings
  • 0 sell ratings
1/19/2024
  • 0 strong buy ratings
  • 10 buy ratings
  • 9 hold ratings
  • 0 sell ratings
3/19/2024
  • 0 strong buy ratings
  • 10 buy ratings
  • 9 hold ratings
  • 0 sell ratings
4/18/2024

Latest Recommendations

  • 0 strong buy ratings
  • 10 buy ratings
  • 9 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/17/2024UBS GroupLower TargetNeutral ➝ Neutral$314.00 ➝ $284.00Low
4/17/2024TD CowenLower TargetBuy ➝ Buy$370.00 ➝ $360.00Low
4/12/2024Truist FinancialReiterated RatingBuy ➝ Buy$320.00Low
4/3/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$329.00Low
3/28/2024Raymond JamesInitiated CoverageMarket PerformN/A
2/7/2024Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$281.00 ➝ $278.00Low
2/7/2024Leerink PartnrsDowngradeOutperform ➝ Market PerformLow
2/7/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$303.00 ➝ $329.00Low
2/7/2024The Goldman Sachs GroupBoost TargetBuy ➝ Buy$313.00 ➝ $350.00Low
2/7/2024SVB LeerinkDowngradeOutperform ➝ Market Perform$324.00 ➝ $318.00Low
2/1/2024OppenheimerReiterated RatingOutperform ➝ Outperform$350.00Low
1/29/2024UBS GroupLower TargetNeutral ➝ Neutral$315.00 ➝ $314.00Low
12/21/2023Daiwa Capital MarketsUpgradeNeutral ➝ Buy$264.00 ➝ $320.00Low
12/19/2023BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$286.00 ➝ $326.00Low
12/12/2023Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$256.00 ➝ $300.00Low
11/29/2023Truist FinancialReiterated RatingBuy ➝ Buy$320.00Low
11/9/2023Deutsche Bank AktiengesellschaftInitiated CoverageHold$240.00Low
11/2/2023UBS GroupLower TargetNeutral ➝ Neutral$272.00 ➝ $268.00Low
11/2/2023Truist FinancialUpgradeHold ➝ Buy$260.00 ➝ $320.00Low
11/1/2023Royal Bank of CanadaBoost TargetSector Perform ➝ Sector Perform$253.00 ➝ $256.00Low
11/1/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$300.00 ➝ $291.00Low
10/20/2023OppenheimerBoost TargetOutperform ➝ Outperform$290.00 ➝ $300.00Low
10/20/2023JPMorgan Chase & Co.Reiterated RatingNeutral ➝ Neutral$270.00Low
10/17/2023ArgusBoost TargetBuy ➝ Buy$280.00 ➝ $310.00Low
10/17/2023Morgan StanleyReiterated RatingEqual Weight$300.00Low
10/12/2023Jefferies Financial GroupReiterated RatingBuy ➝ Buy$310.00Low
10/12/2023Wells Fargo & CompanyBoost Target$265.00 ➝ $320.00Low
10/11/2023Leerink PartnrsUpgradeMarket Perform ➝ OutperformLow
10/11/2023Bank of AmericaInitiated CoverageNeutral$290.00Low
10/11/2023SVB LeerinkUpgradeMarket Perform ➝ Outperform$267.00 ➝ $318.00Low
10/9/2023OppenheimerBoost TargetOutperform ➝ Outperform$280.00 ➝ $290.00Low
10/2/2023BarclaysBoost Target$210.00 ➝ $230.00Low
9/18/2023ArgusBoost TargetBuy ➝ Buy$260.00 ➝ $280.00Low
9/6/2023HSBCInitiated CoverageBuy$320.00Low
9/5/2023Truist FinancialReiterated RatingHold ➝ Hold$260.00Low
8/14/2023Jefferies Financial GroupBoost TargetBuy ➝ Buy$275.00 ➝ $310.00Low
8/14/2023MizuhoBoost TargetNeutral ➝ Neutral$214.00 ➝ $223.00Low
8/4/2023Royal Bank of CanadaBoost TargetSector Perform ➝ Sector Perform$250.00 ➝ $253.00Low
7/25/2023OppenheimerReiterated RatingOutperform ➝ Outperform$280.00Low
7/12/2023Credit Suisse GroupLower Target$220.00 ➝ $200.00Low
7/11/2023BarclaysLower Target$225.00 ➝ $210.00Low
7/7/2023Jefferies Financial GroupLower Target$325.00 ➝ $275.00Low
6/26/2023ArgusLower Target$270.00 ➝ $260.00Low
5/3/2023MizuhoBoost Target$208.00 ➝ $214.00Low
5/1/2023BarclaysLower Target$227.00 ➝ $225.00Low
4/28/2023Piper SandlerLower Target$293.00 ➝ $288.00Low
4/24/2023OppenheimerLower TargetOutperform$292.00 ➝ $290.00Low
4/14/2023BarclaysLower TargetUnderweight$230.00 ➝ $227.00Low
3/13/2023Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$275.00 ➝ $265.00Low
2/13/2023Truist FinancialLower TargetBuy$280.00 ➝ $260.00Low
2/6/2023ArgusLower Target$300.00 ➝ $270.00Low
2/2/2023SVB LeerinkLower TargetMarket Perform$282.00 ➝ $267.00Low
2/2/2023SVB SecuritiesLower Target$282.00 ➝ $267.00Low
2/1/2023OppenheimerLower TargetOutperform$312.00 ➝ $294.00Low
2/1/2023Royal Bank of CanadaLower TargetSector Perform$268.00 ➝ $258.00Low
2/1/2023Wells Fargo & CompanyLower TargetEqual Weight$285.00 ➝ $275.00Low
2/1/2023BMO Capital MarketsLower TargetMarket Perform$276.00 ➝ $253.00Low
2/1/2023CowenLower TargetOutperform$307.00 ➝ $289.00Low
2/1/2023Credit Suisse GroupLower TargetUnderperform$240.00 ➝ $220.00Low
2/1/2023BarclaysLower TargetUnderweight$240.00 ➝ $230.00Low
1/19/2023Piper SandlerLower TargetOverweight ➝ Overweight$299.00 ➝ $293.00Low
1/18/2023BarclaysBoost TargetUnderweight$234.00 ➝ $240.00Low
1/3/2023Wells Fargo & CompanyBoost TargetEqual Weight$250.00 ➝ $285.00Low
12/22/2022SVB LeerinkBoost TargetMarket Perform$256.00 ➝ $282.00Low
12/12/2022Piper SandlerBoost TargetOverweight$297.00 ➝ $299.00Low
12/6/2022OppenheimerBoost TargetOutperform$300.00 ➝ $310.00Low
12/5/2022Piper SandlerBoost Target$278.00 ➝ $297.00Low
11/17/2022Credit Suisse GroupInitiated CoverageUnderperform$240.00Low
11/15/2022OppenheimerBoost Target$300.00N/A
11/8/2022OppenheimerBoost Target$290.00 ➝ $300.00Low
11/8/2022Truist FinancialBoost TargetHold ➝ Hold$266.00 ➝ $280.00Low
11/4/2022Royal Bank of CanadaBoost TargetSector Perform$235.00 ➝ $240.00Low
11/4/2022Morgan StanleyBoost TargetOverweight$279.00 ➝ $282.00Low
11/4/2022Piper SandlerBoost TargetOverweight$265.00 ➝ $278.00Low
10/31/2022BarclaysDowngradeEqual Weight ➝ Underweight$234.00Low
10/12/2022BarclaysLower TargetEqual Weight$236.00 ➝ $234.00Low
10/11/2022Morgan StanleyUpgradeEqual Weight ➝ Overweight$257.00 ➝ $279.00N/A
10/3/2022OppenheimerReiterated RatingOutperform$290.00Low
9/14/2022OppenheimerReiterated RatingOutperform ➝ Outperform$290.00Low
9/13/2022Robert W. BairdReiterated RatingUnderperform$185.00Low
9/1/2022OppenheimerReiterated RatingOutperform ➝ Outperform$290.00Low
8/10/2022OppenheimerReiterated RatingBuy ➝ Buy$290.00Low
8/9/2022Atlantic SecuritiesLower TargetUnderweight$190.00 ➝ $182.00Low
8/5/2022Piper SandlerBoost TargetOverweight$260.00 ➝ $265.00Low
8/5/2022Royal Bank of CanadaBoost Target$224.00 ➝ $236.00Low
7/15/2022Morgan StanleyBoost TargetEqual Weight$239.00 ➝ $253.00Low
6/24/2022OppenheimerReiterated RatingOutperform ➝ Outperform$290.00Low
6/1/2022OppenheimerBoost TargetOutperform$285.00 ➝ $290.00Medium
5/23/2022SVB LeerinkInitiated CoverageMarket Perform$256.00Low
5/10/2022MizuhoBoost Target$202.00 ➝ $208.00Low
5/3/2022OppenheimerDowngradeOutperform$285.00Low
4/28/2022BMO Capital MarketsLower Target$263.00 ➝ $243.00Low
4/28/2022Piper SandlerBoost Target$255.00 ➝ $260.00High
4/12/2022Morgan StanleyLower TargetEqual Weight$238.00 ➝ $237.00Low
4/12/2022BarclaysBoost TargetEqual Weight$233.00 ➝ $236.00Low
3/1/2022MizuhoBoost Target$194.00 ➝ $202.00Low
2/9/2022Morgan StanleyBoost TargetEqual Weight$235.00 ➝ $238.00Low
2/9/2022Jefferies Financial GroupBoost TargetBuy ➝ Buy$266.00 ➝ $280.00Low
2/9/2022OppenheimerBoost TargetOutperform$272.00 ➝ $285.00Medium
2/9/2022BarclaysBoost TargetEqual Weight$228.00 ➝ $233.00Medium
2/9/2022Wells Fargo & CompanyBoost TargetEqual Weight$210.00 ➝ $250.00Medium
1/5/2022Bank of AmericaDowngradeBuy ➝ Neutral$285.00 ➝ $255.00Low
12/21/2021Royal Bank of CanadaBoost TargetSector Perform$216.00 ➝ $218.00Low
12/8/2021Wells Fargo & CompanyInitiated CoverageEqual Weight$213.00 ➝ $210.00Low
12/6/2021The Goldman Sachs GroupInitiated CoverageBuy$258.00High
11/22/2021MizuhoLower TargetNeutral$222.00 ➝ $194.00Medium
11/18/2021BMO Capital MarketsInitiated CoverageMarket Perform$228.00Low
11/3/2021Royal Bank of CanadaLower TargetSector Perform$217.00 ➝ $216.00High
11/3/2021SVB LeerinkLower TargetMarket Perform$234.00 ➝ $216.00High
11/3/2021BarclaysLower TargetEqual Weight$230.00 ➝ $228.00High
11/1/2021OppenheimerLower TargetOutperform$277.00 ➝ $272.00Medium
10/28/2021Robert W. BairdReiterated RatingSellLow
10/12/2021Morgan StanleyLower TargetEqual Weight$251.00 ➝ $235.00High
9/23/2021Daiwa Capital MarketsDowngradeOutperform ➝ Neutral$220.00Low
9/19/2021SVB LeerinkInitiated CoverageHoldMedium
9/17/2021William BlairReiterated RatingHoldHigh
9/10/2021MizuhoInitiated CoverageHold$222.00Low
9/7/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$280.00 ➝ $251.00High
8/5/2021Robert W. BairdReiterated RatingSellHigh
8/4/2021SVB LeerinkLower TargetMarket Perform$238.00 ➝ $234.00High
7/28/2021Robert W. BairdReiterated RatingSell$185.00Low
7/16/2021Morgan StanleyBoost TargetOverweight$278.00 ➝ $280.00Medium
6/25/2021MizuhoReiterated RatingHold$200.00Medium
6/7/2021SVB LeerinkBoost TargetMarket Perform$230.00 ➝ $238.00Low
6/7/2021OppenheimerBoost TargetOutperform$272.00 ➝ $277.00Low
5/31/2021BMO Capital MarketsBoost TargetPositive ➝ Outperform$296.00 ➝ $301.00High
5/17/2021OppenheimerReiterated RatingBuy$270.00Low
5/4/2021Atlantic SecuritiesReiterated RatingNeutral ➝ Underweight$200.00N/A
5/3/2021OppenheimerLower TargetOutperform$275.00 ➝ $265.00Low
4/29/2021Robert W. BairdReiterated RatingSellMedium
4/29/2021Evercore ISIReiterated RatingBuyMedium
4/28/2021Atlantic SecuritiesDowngradeNeutral ➝ Underweight$200.00Low
4/28/2021Credit Suisse GroupLower TargetOutperform$265.00 ➝ $259.00High
4/28/2021SVB LeerinkLower TargetMarket Perform$267.00 ➝ $230.00High
4/28/2021Royal Bank of CanadaLower TargetSector Perform$220.00 ➝ $217.00High
4/28/2021JPMorgan Chase & Co.Reiterated RatingNeutral$215.00High
4/28/2021The Goldman Sachs GroupReiterated RatingBuy$290.00High
4/28/2021BMO Capital MarketsLower TargetOutperform$301.00 ➝ $296.00High
4/26/2021Morgan StanleyLower TargetOverweight$281.00 ➝ $278.00Low
4/19/2021Morgan StanleyBoost TargetOverweight$279.00 ➝ $281.00Low
4/5/2021OppenheimerBoost Target$266.00 ➝ $275.00Low
3/5/2021BarclaysLower TargetEqual Weight$242.00 ➝ $230.00High
3/5/2021Morgan StanleyBoost TargetOverweight$277.00 ➝ $279.00High
3/4/2021JPMorgan Chase & Co.Set TargetNeutral$222.00High
3/4/2021The Goldman Sachs GroupSet TargetBuy$277.00High
3/1/2021SVB LeerinkBoost TargetMarket Perform$252.00 ➝ $260.00Low
2/3/2021Morgan StanleyLower TargetOverweight$285.00 ➝ $277.00Medium
2/3/2021Credit Suisse GroupLower TargetOutperform$280.00 ➝ $265.00Medium
2/3/2021SVB LeerinkLower TargetMarket Perform$253.00 ➝ $245.00Medium
2/3/2021Piper SandlerLower TargetOverweight$280.00 ➝ $260.00Medium
2/3/2021Cantor FitzgeraldBoost TargetPositive ➝ Overweight$280.00 ➝ $295.00Low
1/31/2021OppenheimerReiterated RatingBuy$266.00Low
1/19/2021Morgan StanleyBoost TargetOverweight$276.00 ➝ $285.00Low
1/4/2021Royal Bank of CanadaReiterated RatingNeutralN/A
12/29/2020Daiwa Capital MarketsInitiated CoverageBuy$300.00 ➝ $300.00N/A
12/29/2020Royal Bank of CanadaReiterated RatingNeutralN/A
12/27/2020OppenheimerInitiated CoveragePositive ➝ Buy$274.00 ➝ $266.00N/A
12/27/2020JPMorgan Chase & Co.Reiterated RatingHoldN/A
12/23/2020Royal Bank of CanadaReiterated RatingNeutralN/A
12/16/2020Morgan StanleyBoost TargetOverweight$275.00 ➝ $276.00Low
12/15/2020The Goldman Sachs GroupDowngradeConviction-Buy ➝ BuyMedium
12/9/2020SVB LeerinkBoost TargetMarket Perform$243.00 ➝ $253.00Low
12/8/2020Piper SandlerBoost TargetOverweight$270.00 ➝ $280.00Low
11/16/2020OppenheimerLower TargetOutperform$280.00 ➝ $274.00Low
11/11/2020OppenheimerInitiated CoveragePositive ➝ Buy$275.00 ➝ $280.00Low
11/2/2020MizuhoLower TargetNeutral$260.00 ➝ $215.00Low
10/29/2020Cantor FitzgeraldLower TargetOverweight$279.00 ➝ $278.00Low
10/29/2020BMO Capital MarketsLower TargetOutperform$308.00 ➝ $304.00Low
10/29/2020JPMorgan Chase & Co.Lower TargetNeutral$232.00 ➝ $222.00Medium
10/29/2020SVB LeerinkLower TargetMarket Perform$261.00 ➝ $243.00Medium
10/29/2020Bank of AmericaLower TargetBuy$275.00 ➝ $265.00Medium
10/29/2020Morgan StanleyBoost TargetMarket Perform ➝ Overweight$273.00 ➝ $275.00Medium
10/29/2020BarclaysLower TargetEqual Weight$250.00 ➝ $242.00Low
10/28/2020UBS GroupInitiated CoverageNeutral$232.00High
10/27/2020Credit Suisse GroupLower TargetOutperform$286.00 ➝ $284.00Low
10/26/2020Raymond JamesUpgradeMarket Perform ➝ Outperform$255.00Medium
10/22/2020OppenheimerLower TargetOutperform$280.00 ➝ $275.00Low
10/15/2020Royal Bank of CanadaReiterated RatingHold$223.00Medium
10/13/2020Morgan StanleyLower TargetOverweight$281.00 ➝ $273.00Low
10/12/2020Truist FinancialUpgradeHold ➝ BuyLow
10/9/2020Truist FinancialDowngradeBuy ➝ Hold$251.00Medium
10/9/2020Sanford C. BernsteinDowngradeOutperform ➝ Market PerformMedium
10/6/2020Raymond JamesReiterated RatingOutperform ➝ Market PerformMedium
10/6/2020OppenheimerBoost TargetPositive ➝ Outperform$270.00 ➝ $280.00Medium
9/23/2020William BlairReiterated RatingHoldMedium
9/22/2020JPMorgan Chase & Co.Reiterated RatingHoldHigh
9/21/2020OppenheimerReiterated RatingBuy$270.00Medium
7/30/2020SunTrust BanksBoost TargetBuy$254.00 ➝ $268.00Low
7/29/2020Credit Suisse GroupReiterated RatingBuyLow
7/29/2020Wells Fargo & CompanyBoost TargetEqual Weight ➝ In-Line$237.00 ➝ $247.00Low
7/29/2020Jefferies Financial GroupBoost TargetBuy$285.00 ➝ $300.00Low
7/29/2020Royal Bank of CanadaLower TargetSector Perform$236.00 ➝ $223.00High
7/29/2020Morgan StanleyLower TargetOverweight$285.00 ➝ $281.00Medium
7/29/2020SVB LeerinkBoost TargetMarket Perform$253.00 ➝ $261.00Medium
7/29/2020Cantor FitzgeraldBoost TargetOverweight$263.00 ➝ $279.00Medium
7/29/2020BarclaysBoost TargetEqual Weight$245.00 ➝ $250.00Medium
7/28/2020Piper SandlerBoost TargetPositive ➝ Overweight$255.00 ➝ $270.00Medium
7/28/2020JPMorgan Chase & Co.Boost TargetNeutral$225.00 ➝ $232.00Medium
7/20/2020OppenheimerBoost TargetOutperform$252.00 ➝ $265.00Low
7/20/2020Credit Suisse GroupBoost TargetOutperform$252.00 ➝ $290.00Low
7/15/2020Morgan StanleyBoost TargetOverweight$280.00 ➝ $285.00Low
6/18/2020JPMorgan Chase & Co.Boost TargetNeutral$219.00 ➝ $225.00Medium
6/2/2020SVB LeerinkBoost TargetMarket Perform$249.00 ➝ $253.00High
5/4/2020Cantor FitzgeraldBoost TargetOverweight$255.00 ➝ $263.00Low
5/1/2020CfraBoost TargetBuy$223.00 ➝ $259.00Low
5/1/2020Bank of AmericaBoost TargetBuy$250.00 ➝ $265.00High
5/1/2020SVB LeerinkBoost TargetMarket Perform$219.00 ➝ $249.00High
5/1/2020Morgan StanleyBoost TargetOverweight$267.00 ➝ $280.00High
5/1/2020BMO Capital MarketsBoost TargetPositive ➝ Outperform$274.00 ➝ $291.00High
5/1/2020Wells Fargo & CompanyBoost TargetEqual Weight$220.00 ➝ $237.00High
5/1/2020OppenheimerInitiated CoverageBuy$252.00Medium
4/30/2020MizuhoReiterated RatingHold$215.00Medium
4/30/2020Piper SandlerBoost TargetOverweight$235.00 ➝ $255.00Medium
4/26/2020OppenheimerBoost TargetOutperform$240.00 ➝ $250.00Medium
4/15/2020Morgan StanleyLower TargetOverweight$277.00 ➝ $267.00Low
4/15/2020GuggenheimInitiated CoverageNeutral$225.00Low
3/31/2020Wolfe ResearchInitiated CoverageMarket Perform$218.00Medium
3/29/2020Raymond JamesUpgradeMarket Perform ➝ Outperform$255.00High
3/26/2020OppenheimerLower TargetOutperform$250.00 ➝ $240.00High
3/13/2020CfraUpgradeHold ➝ BuyHigh
3/9/2020OppenheimerLower Target$256.00 ➝ $250.00Medium
3/5/2020Bank of AmericaUpgradeNeutral ➝ Buy$245.00 ➝ $250.00Medium
2/27/2020BarclaysInitiated CoverageEqual Weight$235.00High
2/6/2020ArgusReiterated RatingBuy$265.00 ➝ $265.00Low
2/3/2020SunTrust BanksBoost TargetBuy ➝ Buy$254.00 ➝ $265.00Low
2/2/2020Credit Suisse GroupReiterated RatingBuy$252.00Low
2/2/2020JPMorgan Chase & Co.Reiterated RatingNeutral ➝ HoldLow
1/31/2020CfraBoost TargetHold$215.00 ➝ $223.00High
1/31/2020CowenReiterated RatingBuyHigh
1/31/2020Robert W. BairdDowngradeNeutral ➝ Underperform$173.00 ➝ $185.00High
1/30/2020MizuhoReiterated RatingHold$215.00High
1/24/2020JPMorgan Chase & Co.Set TargetNeutral$198.00Low
1/23/2020CitigroupBoost TargetBuy ➝ In-Line$245.00 ➝ $275.00Low
1/22/2020UBS GroupBoost TargetNeutral$194.00 ➝ $238.00Low
1/21/2020OppenheimerBoost Target$250.00 ➝ $260.00Low
1/21/2020Evercore ISIUpgradeIn-Line ➝ OutperformMedium
1/19/2020JPMorgan Chase & Co.Reiterated RatingHoldMedium
1/17/2020Morgan StanleyLower TargetOverweight$280.00 ➝ $277.00Low
1/14/2020Cantor FitzgeraldReiterated RatingBuy$255.00Low
1/9/2020BMO Capital MarketsBoost TargetOutperform$240.00 ➝ $275.00Low
12/23/2019Raymond JamesInitiated CoverageMarket PerformN/A
12/19/2019CowenBoost TargetOutperform$253.00 ➝ $277.00Medium
12/17/2019Morgan StanleyInitiated CoverageOverweight$280.00Low
12/13/2019Credit Suisse GroupBoost TargetOutperform$235.00 ➝ $250.00Medium
12/9/2019ArgusBoost TargetPositive ➝ Buy$240.00 ➝ $265.00Low
11/12/2019SunTrust BanksInitiated CoverageBuy$256.00Low
11/5/2019Cantor FitzgeraldUpgradeNeutral ➝ Overweight$230.00 ➝ $255.00Low
10/30/2019SVB LeerinkBoost TargetMarket Perform$189.00 ➝ $205.00High
10/16/2019Bank of AmericaInitiated CoverageNeutral$215.00Low
10/14/2019Sanford C. BernsteinInitiated CoverageOutperformLow
9/30/2019JPMorgan Chase & Co.Reiterated RatingHoldMedium
9/30/2019The Goldman Sachs GroupSet TargetBuy$243.00Medium
9/30/2019BMO Capital MarketsSet TargetBuy$240.00Medium
9/30/2019Cantor FitzgeraldSet TargetHold$230.00Medium
9/30/2019SVB LeerinkSet TargetHold$189.00Medium
9/30/2019Royal Bank of CanadaReiterated RatingHoldMedium
9/29/2019CowenSet TargetBuy$231.00Medium
9/29/2019MizuhoReiterated RatingHold$212.00Medium
9/12/2019SVB LeerinkReiterated RatingHoldLow
9/9/2019BMO Capital MarketsReiterated RatingBuyHigh
9/9/2019OppenheimerSet TargetBuy$240.00High
9/6/2019JPMorgan Chase & Co.Set TargetHold$198.00High
9/5/2019Cantor FitzgeraldReiterated RatingNeutral$221.00 ➝ $230.00Low
8/30/2019William BlairReiterated RatingHoldMedium
8/29/2019JPMorgan Chase & Co.Boost TargetNeutral$191.00 ➝ $198.00Low
8/27/2019OppenheimerBoost Target$230.00 ➝ $240.00Low
8/27/2019BMO Capital MarketsBoost TargetOutperform$230.00 ➝ $240.00Low
8/27/2019JPMorgan Chase & Co.Reiterated RatingHold$191.00 ➝ $198.00Low
8/27/2019Wells Fargo & CompanyReiterated RatingMarket Perform$202.00 ➝ $220.00Low
8/27/2019Royal Bank of CanadaBoost TargetSector Perform$192.00 ➝ $206.00Low
8/26/2019Piper Sandler CompaniesBoost TargetOverweight$210.00 ➝ $218.00Low
8/22/2019CowenSet TargetBuy$231.00Low
8/21/2019Royal Bank of CanadaBoost TargetSector Perform$192.00Low
8/19/2019MizuhoDowngradeBuy ➝ Neutral$208.00 ➝ $212.00Low
8/16/2019Credit Suisse GroupReiterated RatingOutperform$202.00 ➝ $225.00Low
8/13/2019OppenheimerBoost TargetOutperform$210.00 ➝ $230.00Medium
8/12/2019CitigroupReiterated RatingBuyLow
8/12/2019Credit Suisse GroupSet TargetBuy$202.00Low
8/12/2019Wells Fargo & CompanyBoost TargetMarket Perform ➝ Market Perform$197.00 ➝ $202.00High
8/11/2019Evercore ISIReiterated RatingHoldHigh
8/11/2019Royal Bank of CanadaReiterated RatingHoldHigh
8/10/2019Piper Sandler CompaniesSet TargetBuy$210.00Low
8/9/2019JPMorgan Chase & Co.Reiterated RatingHoldLow
7/31/2019BMO Capital MarketsSet TargetBuy$230.00Low
7/15/2019Morgan StanleyLower TargetOverweight$211.00 ➝ $207.00Low
7/1/2019MizuhoReiterated RatingBuy$208.00Low
6/24/2019MizuhoReiterated RatingBuy$208.00Low
5/24/2019OppenheimerSet TargetBuy$210.00Medium
5/22/2019CitigroupUpgradeNeutral ➝ Buy$211.00 ➝ $205.00Low
5/21/2019Royal Bank of CanadaReiterated RatingNeutral$192.00Low
5/20/2019Credit Suisse GroupInitiated CoverageOutperform$208.00 ➝ $208.00Low
5/17/2019MizuhoReiterated RatingBuy$208.00Low
5/15/2019JPMorgan Chase & Co.Reiterated RatingHold$190.00Medium
5/10/2019MizuhoSet TargetBuy$208.00High
5/1/2019CowenReiterated RatingBuy$229.00High
4/22/2019MizuhoSet TargetBuy$208.00Low
(Data available from 4/18/2019 forward)

News Sentiment Rating

0.82 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 35 very positive mentions
  • 56 positive mentions
  • 12 negative mentions
  • 1 very negative mentions
9/21/2023
  • 39 very positive mentions
  • 39 positive mentions
  • 7 negative mentions
  • 4 very negative mentions
10/21/2023
  • 19 very positive mentions
  • 53 positive mentions
  • 3 negative mentions
  • 3 very negative mentions
11/20/2023
  • 42 very positive mentions
  • 39 positive mentions
  • 1 negative mentions
  • 5 very negative mentions
12/20/2023
  • 44 very positive mentions
  • 26 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
1/19/2024
  • 47 very positive mentions
  • 52 positive mentions
  • 13 negative mentions
  • 6 very negative mentions
2/18/2024
  • 43 very positive mentions
  • 52 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
3/19/2024
  • 43 very positive mentions
  • 23 positive mentions
  • 6 negative mentions
  • 1 very negative mentions
4/18/2024

Current Sentiment

  • 43 very positive mentions
  • 23 positive mentions
  • 6 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Amgen logo
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Read More

Today's Range

Now: $262.75
Low: $262.58
High: $265.92

50 Day Range

MA: $277.34
Low: $262.75
High: $294.43

52 Week Range

Now: $262.75
Low: $211.71
High: $329.72

Volume

2,082,465 shs

Average Volume

2,851,966 shs

Market Capitalization

$140.81 billion

P/E Ratio

21.04

Dividend Yield

3.39%

Beta

0.58

Frequently Asked Questions

What sell-side analysts currently cover shares of Amgen?

The following Wall Street research analysts have issued reports on Amgen in the last year: Argus, Bank of America Co., Barclays PLC, BMO Capital Markets, Credit Suisse Group AG, Daiwa Capital Markets, Deutsche Bank Aktiengesellschaft, HSBC Holdings plc, Jefferies Financial Group Inc., JPMorgan Chase & Co., Leerink Partnrs, Mizuho, Morgan Stanley, Oppenheimer Holdings Inc., Piper Sandler, Raymond James, Royal Bank of Canada, StockNews.com, SVB Leerink LLC, TD Cowen, The Goldman Sachs Group, Inc., Truist Financial Co., UBS Group AG, and Wells Fargo & Company.
View the latest analyst ratings for AMGN.

What is the current price target for Amgen?

21 Wall Street analysts have set twelve-month price targets for Amgen in the last year. Their average twelve-month price target is $296.95, suggesting a possible upside of 13.0%. TD Cowen has the highest price target set, predicting AMGN will reach $360.00 in the next twelve months. Credit Suisse Group AG has the lowest price target set, forecasting a price of $200.00 for Amgen in the next year.
View the latest price targets for AMGN.

What is the current consensus analyst rating for Amgen?

Amgen currently has 9 hold ratings and 10 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for AMGN.

What other companies compete with Amgen?

Other companies that are similar to Amgen include Gilead Sciences, Seagen, Moderna, Pfizer and Intuitive Surgical. Learn More about companies similar to Amgen.

How do I contact Amgen's investor relations team?

Amgen's physical mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The medical research company's listed phone number is (805) 447-1000 and its investor relations email address is [email protected]. The official website for Amgen is www.amgen.com. Learn More about contacing Amgen investor relations.